Sicart Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Sicart Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.31M	Sell	6,912 -49	-0.7%	-$33.4K	1.06%	31
2026 Q1	$5.38M	Hold	6,961	–	–	1.38%	27
2025 Q4	$5.37M	Sell	6,961 -20	-0.3%	-$13.6K	1.43%	27
2025 Q3	$3.93M	Buy	+6,981	New	+$3.95M	1.06%	30
2024 Q2	–	Sell	-419	Closed	-$403K	–	78
2024 Q1	$403K	Hold	419	–	–	0.15%	57
2023 Q4	$368K	Hold	419	–	–	0.14%	54
2023 Q3	$345K	Hold	419	–	–	0.14%	53
2023 Q2	$301K	Sell	419 -48	-10%	-$37K	0.12%	55
2023 Q1	$384K	Sell	467 -3	-0.6%	-$2.26K	0.15%	54
2022 Q4	$339K	Hold	470	–	–	0.12%	60
2022 Q3	$324K	Sell	470 -56	-11%	-$35.2K	0.11%	60
2022 Q2	$311K	Sell	526 -12	-2%	-$7.8K	0.1%	62
2022 Q1	$376K	Sell	538 -382	-42%	-$242K	0.1%	63
2021 Q4	$591K	Sell	920 -128	-12%	-$78.7K	0.15%	61
2021 Q3	$634K	Sell	1,048 -15	-1%	-$9.31K	0.17%	58
2021 Q2	$594K	Hold	1,063	–	–	0.14%	66
2021 Q1	$503K	Buy	+1,063	New	+$518K	0.13%	66

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sicart Associates's REGN Position: Q2 2026 in Review

Sicart Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 0.7% in Q2 2026, selling an estimated $33.4K and leaving 6,912 shares worth $4.31M. The position accounts for 1.06% of the portfolio, ranked #31.

Sicart Associates first reported a position in REGN in Q1 2021 and has held it in 17 quarters since. The position peaked at $5.38M in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Sicart Associates held 6,912 shares of Regeneron Pharmaceuticals worth $4.31M as of Q2 2026.
Sicart Associates sold 49 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $33.4K.
Regeneron Pharmaceuticals made up 1.06% of Sicart Associates's portfolio in Q2 2026, its #31 holding.
Sicart Associates first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
Sicart Associates's Regeneron Pharmaceuticals position peaked at $5.38M in Q1 2026.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sicart Associates's 13F filing for Q2 2026, filed 11 Aug 2026.